Transthyretin (TTR) amyloidosis is a progressive multisystem disorder caused by misfolding and deposition of TTR protein as amyloid fibrils in tissues, leading to polyneuropathy, cardiomyopathy, and autonomic dysfunction in hereditary (hATTR) and wild-type (ATTRwt) forms. Historically managed with supportive care, newer therapies targeting TTR production are expanding options for disease modification.
RNA interference (RNAi) therapeutics are designed to reduce hepatic production of TTR. Delivered subcutaneously using GalNAc conjugation for hepatocyte uptake, these agents promote degradation of TTR messenger RNA, lowering circulating TTR levels. Clinical studies in hATTR polyneuropathy and ATTR cardiomyopathy have demonstrated improvements in measures of neuropathy, functional status, and quality of life compared with placebo.
These therapies are administered infrequently (eg, every 3 months), which may support adherence. In clinical trials, RNAi agents have generally been well tolerated, with reported injection-site reactions and the need for periodic laboratory monitoring.
As the treatment landscape evolves, RNAi approaches offer a strategy to reduce TTR production and may complement other therapeutic modalities, such as TTR stabilizers.
How might RNAi-based TTR reduction influence management across different stages of disease in your practice? What factors guide your approach to sequencing or combining therapies in TTR amyloidosis?
Share
-
Liang Lu8minRNAi-based TTR silencer therapy has proven therapeutic role across disease stages by significant reducing serum TTR level and improving quality of life. The choice between sequencing of TTR stabalizers or silencers or combining therapies depends on clinical evaluation and discussion. -
Joel Washinsky2dRNAi-based TTR reduction is having widespread use for different phenotypes.
-
SACHINKUMAR PANCHAL2wRNAi-based TTR reduction is becoming a cornerstone for neuropathy-predominant and early disease, with growing relevance in mixed phenotypes. Sequencing is driven by phenotype, stage, progression rate, and practicality, while combination approaches remain promising but not yet routine.